310 results on '"Munshi, N. C."'
Search Results
2. Nucleotide excision repair is a potential therapeutic target in multiple myeloma
3. Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma
4. RETRACTED ARTICLE: SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
5. P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
6. Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
7. CSNK1α1 mediates malignant plasma cell survival
8. Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma
9. A multiepitope of XBP1, CD138 and CS1 peptides induces myeloma-specific cytotoxic T lymphocytes in T cells of smoldering myeloma patients
10. Gene expression profile alone is inadequate in predicting complete response in multiple myeloma
11. Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
12. Targeting homologous recombination and telomerase in Barrett’s adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth
13. Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
14. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications
15. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
16. Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
17. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo
18. Challenges in multiple myeloma diagnosis and treatment
19. Minor clone provides a reservoir for relapse in multiple myeloma
20. Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma
21. Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome
22. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells
23. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition
24. The use of novel agents in the treatment of relapsed and refractory multiple myeloma
25. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
26. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
27. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
28. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
29. Biological pathways and in vivo antitumor activity induced by Atiprimod in myeloma
30. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma
31. Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs
32. Bone marrow stromal cells as a vehicle for gene transfer
33. Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
34. IL-17 Promotes Tumor cell Growth and Survival, and Inhibits Immune Function in Myeloma: B623
35. Targeting the Sp1 Transcription Factor in Multiple Myeloma: B569
36. Anti-DKK1 mAb (BHQ880) as a Potential Therapeutic Agent for Multiple Myeloma: B563
37. Unraveling the Synergism of Nab-Rapamycin and Perifosine Combination in Multiple Myeloma: B469
38. A Novel Small-Molecule Inhibitor RGB 286638 Induces Apoptosis and Necrosis in Multiple Myeloma: B483
39. AT7519, a Multi-Cyclin Dependent Kinase Inhibitor, Induces Apoptosis in Multiple Myeloma via GSK3β: B457
40. Targeting Myeloma Bone Disease via Activin A Inhibition: B357
41. CAL-101: A Selective Inhibitor of PI3K p110Δ for the Treatment of Multiple Myeloma: B037
42. CS1 Promotes Multiple Myeloma Cell Adhesion, Clonogenic Growth, and Tumorigenicity via c-Maf Mediation: B026
43. MicroRNA Profile Identifies Distinct Clinically Relevant Subgroups in Multiple Myeloma: A628
44. Alternate Splicing Is Frequently Observed in Myeloma and Has Impact on Clinical Outcome: A627
45. Phase I Trial of CCI-779 and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma: A573
46. Phase II Trial of Bortezomib and Rituximab in Relapsed/Refractory Waldenström Macroglobulinemia: A535
47. Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma: A224
48. Phase I/II Trial of Perifosine + Bortezomib in Rel/Ref MM Patients Previously Treated with Bortezomib: A349
49. Endothelial Stress Markers in Multiple Myeloma Patients: A342
50. Lenalidomide, Bortezomib, and Dexamethasone Is Active in High-Risk Relapsed/Refractory Myeloma: A227
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.